Advancing Precision Medicine and Regenerative Therapies for Retinal Diseases
Ocular Stem Cell and Transnational Research Section at the National Eye Institute (NEI), NIH, is focused on understanding the mechanisms of human retinal diseases and developing innovative therapeutic approaches to prevent vision loss and restore sight. Our research integrates stem cell biology, tissue engineering, artificial intelligence, functional genomics, and regenerative medicine to bridge fundamental discoveries in human biology with clinical translation. Using human induced pluripotent stem cells (iPSCs), we develop physiologically relevant models of retinal tissues to investigate disease mechanisms, identify therapeutic targets, and advance precision medicine approaches for age-related macular degeneration (AMD) and other inherited and acquired retinal degenerative diseases.
A major focus of our laboratory is developing iPSC-derived retinal pigment epithelium (RPE) tissue patches for transplantation into patients with advanced AMD. This program has progressed from fundamental stem cell research and tissue engineering to clinical testing, establishing a translational framework for developing regenerative therapies. Unlike conventional pharmaceuticals, transplanted cells represent living drugs that can persist long-term, adapt to their environment, and dynamically interact with surrounding host tissues. We seek to understand how the unique pathological environment of each patient influences the survival, integration, and function of transplanted cells, and how these cells, in turn, modify the recipient tissue, providing a new paradigm for precision regenerative medicine. Using the same principle, we are currently developing a photoreceptor cell therapy for retinitis pigmentosa and AMD.
In parallel, we use patient-derived iPSCs and engineered human retinal tissues to recreate key aspects of retinal degeneration in vitro. Our research investigates how genetic susceptibility, aging, complement activation, lipid dysregulation, oxidative stress, and mitochondrial dysfunction converge to drive cellular degeneration. By combining these disease models with CRISPR-based functional genomics, high-content imaging, and molecular profiling, we aim to identify causal disease mechanisms and discover therapeutic interventions capable of restoring cellular homeostasis. Our work has led to repurposing of drugs like metformin and pioglitazone for AMD and monogenic retinal degenerative diseases such as ciliopathies. Currently, we are in the process of developing gene agnostic gene therapies for these conditions.
We are also pioneering the integration of artificial intelligence and cellular digital twins into human disease modeling. By combining high-resolution three-dimensional imaging, machine learning, and quantitative analysis of subcellular architecture, we generate computational representations of human RPE cells that reveal how organelle organization, cellular polarity, and tissue architecture change during development, aging, and disease. These approaches enable the discovery of previously unrecognized cellular biomarkers and provide a foundation for predicting disease-associated cellular states and responses to therapeutic interventions.
Together, these interconnected research programs establish a comprehensive framework linking human disease modeling, mechanistic discovery, computational prediction, and clinical translation. Our overarching vision is to transform regenerative medicine from a one-size-fits-all approach into a predictive, personalized therapeutic strategy, in which the unique biology of each patient informs the development, selection, and evaluation of treatments capable of preserving and restoring vision.
Dr. Kapil Bharti and Dr. Fnu Ruchi

